Recruiting

Testing a new medication for sickle cell disease complications

Plain-English translation of NCT07187973 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated June 2026 · How we translate trials

Read our Sickle Cell Disease research guide →

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This trial is testing a new medication called in adults with sickle cell disease (SCD). The study will gradually increase the dose of this medication for each participant and carefully monitor how safe it is, how well the body tolerates it, and how it affects the body's blood cells. Researchers want to learn whether this treatment might help reduce sickle cell complications.

Sickle cell disease causes painful complications like vaso-occlusive crises (sudden pain episodes), organ damage, and other serious health problems. This trial exists to see if this new medication might offer patients another treatment option to help manage their condition.

Do you qualify?

You likely qualify if…

you are 18 years or older
you have been diagnosed with sickle cell disease (either HbSS or HbSC type)
you have experienced sickle cell-related complications in the past year, such as pain episodes, vision problems, stroke, bone damage, hearing loss, or specific organ complications
your hemoglobin level is at least 7.0 g/dL (and at least 9.0 g/dL if you are one of the first two participants)
your iron storage levels and reticulocyte counts (young red blood cells) fall within acceptable ranges

You likely don't qualify if…

you have an abnormal alpha globin gene screen result
you are taking sickle cell medications (hydroxyurea, L-glutamine, or crizanlizumab) and have adjusted your dose within the past 2 months
you are female and pregnant, or planning to become pregnant during the study and for 120 days after treatment ends
you are male and cannot commit to using double birth control methods with your partner for 120 days after the study medication ends
your ferritin (iron storage) level is 1000 ng/mL or higher

What participation looks like

You will take the medication by mouth at gradually increasing doses throughout the study. You'll visit the study clinic multiple times so doctors can check your blood work, monitor your symptoms, and watch for any side effects. The entire study will last several months. You'll need to use effective birth control during treatment and for 120 days afterward if you are capable of becoming pregnant or fathering children.

AI-generated summary from trial data · Jun 5, 2026 · Not medical advice

Trial locations(8 sites)

United States

University of Alabama at Birmingham, Birmingham, Alabama

Emory University, Atlanta, Georgia

Augusta University, Augusta, Georgia

University of Illinois Hospital and Health Sciences System, Chicago, Illinois

Innovative Hematology - Indiana Hemophilia & Thrombosis Center, Indianapolis, Indiana